Many hematologic malignancies carry characteristic chromosomal translocations. Correct identification of fusion genes can ensure an accurate diagnosis and prognosis is made and can assist in making treatment decisions, stratification, and disease monitoring. Current methodologies used to detect fusion genes can be laborious and time-consuming, typically involving karyotyping, followed by fluorescence in situ hybridization (FISH) and molecular analysis based on reverse transcriptase polymerase chain reaction (RT-PCR).
The gene sequence called BCR-ABL1 confirms the diagnosis of CML, and a form of acute lymphoblastic lymphoma (ALL) called Philadelphia chromosome (Ph)-positive ALL. Once CML or Ph-positive ALL has been diagnosed, BCR-ABL1 quantitative genetic testing is ordered periodically (typically every 3 months) to monitor the response to treatment and monitor for recurrence.
Fusion genes | BCR-ABL1 p190, p210, and p230 |
---|---|
Sample types | Bone marrow, peripheral blood, FFPE, and cell lines |
Reaction Volume | 25 ul |
Reaction time | 2-3 hour |
Internal control | GUSB as housekeeping genes, 2 positive control, 3 negative control |
Sensitivity | 10-4 |
Instruments | Compatible with Bio-Rad CFX96, iCycler, ABI7500, Stratagene Mx3000P/Mx3005P, and other commonly used RT-qPCR machines. |
Cat. No. | Description | Size |
1-100-13020 | Q-Fusion BCR-ABL1 Genotyping Kit | 20-reactions |
1-100-14020 | Q-Fusion BCR-ABL1 p190 Quantification Kit | 20-reactions |
1-100-15020 | Q-Fusion BCR-ABL1 p210 Quantification Kit | 20-reactions |
The BCR-ABL1 Genotyping and Quantification Test kit is a CE-marked product for In Vitro Diagnostic Use.
The BCR-ABL1 Genotyping and Quantification Test kit is not FDA-cleared.
Please contact us for a quote or with any questions about our products.
There are no products |